MRSN - Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of Antibody Drug Conjugates (ADCs) for cancer patients with unmet needs. The company is headquartered in Cambridge, Massachusetts.

52W High

$70.75

52W Low

$5.21

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.86

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.20

EV/Revenue (<3 favorable)

4.66

P/S (TTM) (<3 favorable)

0.98

P/B (<3 favorable)

32.03

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.46%

Institutions (25–75% balanced)

62.48%

Shares Outstanding

4,990,700

Float

4,063,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

34,769,000

Gross Profit (TTM)

-36,879,000

EPS (TTM)

-14.79

Profit Margin (>10% good)

-2.13%

Operating Margin (TTM) (higher better)

-6.73%

ROE (TTM) (>15% strong)

-5.05%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.33

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—